The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 6, 2014, Pages 1227-1239

  Stankovic, Tatjana ^a   Skowronska, Anna ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

11q deletion; ATM mutations; CLL; Prognosis

Indexed keywords

ABELSON KINASE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; B LYMPHOCYTE RECEPTOR; BLOOM SYNDROME HELICASE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; LENALIDOMIDE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TUMOR MARKER;

APOPTOSIS; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL CYCLE ARREST; CHROMOSOME 11Q; CHROMOSOME 11Q22.3 DELETION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CLONAL EVOLUTION; COHORT ANALYSIS; CYTOTOXICITY ASSAY; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEXT GENERATION SEQUENCING; NONHUMAN; NULL ALLELE; OVERALL SURVIVAL; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; SEQUENCE ANALYSIS; TUMOR XENOGRAFT; CHROMOSOME 11; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROGNOSIS;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; CLONAL EVOLUTION; DISEASE PROGRESSION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84901220752     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.829919     Document Type: Review

References (152)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815
2. Rawstron AC, Hillmen P. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. Best Pract Res Clin Haematol 2010; 23: 61-69
3. Chiorazzi N, Efremov DG. Chronic lymphocytic leukemia: A tale of one or two signals? Cell Res 2013; 23: 182-185
4. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234
5. Binet JL, Auquier A, Dighiero G, et al. Anew prognostic classifi cation of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206. (Pubitemid 11064396
6. Montserrat E, Sanchez-Bisono J, Vinolas N, et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: Analysis of its prognostic signifi cance. Br J Haematol 1986; 62: 567-575. (Pubitemid 16130192
7. Gentile M, Cutrona G, Neri A, et al. Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages. Haematologica 2009; 94: 887-888
8. Damle R N, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847. (Pubitemid 29430399
9. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated wiTha more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854. (Pubitemid 29430400
10. Oscier D G, Gardiner A C, Mould S J, et al. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184
11. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416
12. Krober A, Bloehdorn J, Hafner S, et al. Additional genetic highrisk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. JClin Oncol 2006; 24: 969-975. (Pubitemid 46646223
13. Wiestner A, Rosenwald A, Barry T S, et al. ZAP-70 expression identifi es a chronic lymphocytic leukemia subtype wiThunmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profi le. Blood 2003; 101: 4944-4951. (Pubitemid 36857758
14. Rassenti L Z, Huynh L, Toy T L, et al. ZAP-70 compared wiThimmunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901. (Pubitemid 39096916
15. Orchard J A, Ibbotson R E, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363 : 105-111. (Pubitemid 38068326
16. Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 415-424. (Pubitemid 47263408
17. Seiler T, Dohner H, Stilgenbauer S. Risk stratifi cation in chronic lymphocytic leukemia. Semin Oncol 2006; 33: 186-194
18. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211-219
19. Wierda WG, O'Brien S, Wang X, et al. Characteristics associated wiThimportant clinical end points in patients wiThchronic lymphocytic leukemia at initial treatment. JClin Oncol 2009; 27: 1637-1643
20. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007; 110: 3352-3359. (Pubitemid 350106329
21. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia:Association wiThprog ression and fl udarabine-refractoriness. Blood 2011; 118 : 6904-6908
22. Balatti V, Lerner S, Rizzotto L, et al. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia 2013; 27: 740-743
23. Oscier DG, Rose-Zerilli MJ, Winkelmann N, et al. The clinical signifi cance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013; 121: 468-475
24. Zenz T, Mertens D, Dohner H, et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011; 25: 131-137
25. Foà R, Del Giudice I, Guarini A, et al. Interphase fl uorescence in situ hybridization analysis of del(11)(q23) and del(17)(p13) in chronic lymphocytic leukemia. A study of 40 early-onset patients. Cancer Genet Cytogenet 2003; 140: 31-36
26. Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica 2013; 98: 675-685
27. Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50
28. Zenz T, Frohling S, Mertens D, et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010; 23: 71-84
29. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916. (Pubitemid 32064784
30. Hallek M, Cheson B D, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456
31. Stilgenbauer S, Bullinger L, Lichter P, et al. German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia. Genetics of chronic lymphocytic leukemia: Genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002; 16: 993-1007
32. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated wiTha complex aberrant karyotype. Leukemia 2009; 23: 117-124
33. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995-1004
34. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated wiThpoor prognosis in chronic lymphocytic leukemia:results from a detailed genetic characterization wiThlongterm follow-up. Blood 2008; 112: 3322-3329
35. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy wiThpurine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589
36. Lozanski G, Heerema N A, Flinn I W, et al. Alemtuzumab is an Effective therapy for chronic lymphocytic leukemia wiThp53 mutations and deletions. Blood 2004; 103: 3278-3281. (Pubitemid 38525651
37. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients wiThp53 abnormalities. Ann Hematol 2003; 82: 759-765
38. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination wiThhigh-Dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients wiThp53 defects. Leukemia 2006; 20: 1441-1445. (Pubitemid 44084061
39. Gribben JG. How I treat CLL up front. Blood 2009; 115: 187-197
40. Fegan C, Robinson H, Thompson P, et al. Karyotypic evolution in CLL: Identifi cation of a new sub-group of patients wiThdeletions of 11q and advanced or progressive disease. Leukemia 1995; 9: 2003-2008
41. Neilson J R, Auer R, White D, et al. Deletions at 11q identify a subset of patients wiThtypical CLL who show consistent disease progression and reduced survival. Leukemia 1997; 11: 1929-1932. (Pubitemid 27485140
42. Dohner H, Stilgenbauer S, James M R, et al. 1 1q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997 ; 89: 2516-2522
43. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996; 93: 11837-11841. (Pubitemid 26347210
44. Gunn SR, Hibbard MK, Ismail SH, et al. Atypical 11q deletions identifi ed by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 2009; 23: 1011-1017
45. Gunnarsson R, Mansouri L, Isaksson A, et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011; 96: 1161-1169
46. Gardiner A, Parker H, Glide S, et al. Anew minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia. Leuk Res 2012; 36: 307-310
47. Wierda WG, O'Brien S, Wang X, et al. Multivariable model for time to fi rst treatment in patients wiThchronic lymphocytic leukemia. JClin Oncol 2011; 29: 4088-4095
48. Marasca R, Maffei R, Martinelli S, et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia:prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol 2013; 31: 348-355
49. Roos G, Kröber A, Grabowski P, et al. Short telomeres are associated wiThgenetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood 2008; 111: 2246-2252
50. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011; 118: 3051-3061
51. Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia wiThelevated genomic complexity is associated wiThmultiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res 2010; 16: 4135-4147
52. Kujawski L, Ouillette P, Erba H, et al. Genomic complexity identifi es patients wiThaggressive chronic lymphocytic leukemia. Blood 2008; 112: 1993-2003
53. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-Term follow-up of patients wiThuntreated early-stage chronic lymphocytic leukemia. JClin Oncol 2006; 24: 4634-4641. (Pubitemid 46630962
54. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia:Acquisition of high-risk genomic aberrations associated wiThunmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-1245. (Pubitemid 350144184
55. Britt-Compton B, Lin TT, Ahmed G, et al. Extreme telomere erosion in ATM-mutated and 11q-Deleted CLL patients is independent of disease stage. Leukemia 2012; 26: 826-830
56. Catovsky D, Richards S, Matutes E, et al. Assessment of fl udarabine plus cyclophosphamide for patients wiThchronic lymphocytic leukaemia (the LRF CLL4 Trial): Arandomised controlled trial. Lancet 2007; 370: 230-239. (Pubitemid 47069536
57. Dickinson JD, Smith LM, Sanger WG, et al. Unique gene expression and clinical characteristics are associated wiThthe 11q23 deletion in chronic lymphocytic leukaemia. Br J Haematol 2005; 128: 460-471. (Pubitemid 40283162
58. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients wiThchronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804. (Pubitemid 350010635
59. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared wiThchlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. JClin Oncol 2007; 25: 5616-5623
60. Oscier D, Wade R, Davis Z, et al. Prognostic factors identifi ed three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010; 95: 1705-1712
61. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. JClin Oncol 2010; 28: 4473-4479
62. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy wiThfl udarabine and rituximab in chronic lymphocytic leukemia: Justifi cation for risk-Adapted therapy. J Clin Oncol 2006; 24: 437-443. (Pubitemid 46655595
63. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fl udarabine and cyclophosphamide in patients wiThchronic lymphocytic leukaemia:Arandomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174
64. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fl udarabine-refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. JClin Oncol 2009; 27: 3994-4001
65. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly Effective treatment for relapsed patients wiThCLL. Blood 2011; 117 : 3016-3024
66. Tsimberidou AM, Tam C, Abruzzo LV, et al. Chemoimmunotherapy may overcome the adverse prognostic signifi cance of 11q deletion in previously untreated patients wiThchronic lymphocytic leukemia. Cancer 2009; 115: 373-380
67. Lozanski G, Ruppert AS, Heerema NA, et al. Variations of the ataxia telangiectasia mutated gene in patients wiThchronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: A Cancer and Leukemia Group B study. Leuk Lymphoma 2012; 53: 1743-1748
68. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients wiThrelapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297
69. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated wiThmarked clinical Efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399-404. (Pubitemid 46105932
70. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates wiThfl udarabine chemorefractoriness in TP53 wild-Type chronic lymphocytic leukemia. Blood 2012; 119: 2854-2862
71. Lavin MF, Scott S, Gueven N, et al. Functional consequences of sequence alterations in the ATM gene. DNA Repair (Amst) 2004; 3 : 1197-1205. (Pubitemid 38997963
72. Taylor AM, Metcalfe JA, Thick J, et al. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87: 423-438
73. Bosotti R, Isacchi A, Sonnhammer EL. FAT: A novel domain in PIK-related kinases. Trends Biochem Sci 2000; 25: 225-227. (Pubitemid 30236217
74. Sun Y, Xu Y, Roy K, et al. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 2007; 27: 8502-850
75. Beamish H, Kedar P, Kaneko H, et al. Functional link between BLM defective in Bloom's syndrome and the ataxia-Telangiectasiamutated protein, ATM. JBiol Chem 2002; 277: 30515-30523. (Pubitemid 34970744
76. Fernandes N, Sun Y, Chen S, et al. DNA damage-induced association of ATM wiThits target proteins requires a protein interaction domain in the N terminus of ATM. J Biol Chem 2005; 280: 15158-15164. (Pubitemid 40562870
77. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434 : 605-611
78. Young DB, Jonnalagadda J, Gatei M, et al. Identifi cation of domains of ataxia-Telangiectasia mutated required for nuclear localization and chromatin association. J Biol Chem 2005; 280: 27587-27594. (Pubitemid 41076870
79. Seidel JJ, Anderson CM, Blackburn EH. Anovel Tel1/ATM N-Terminal motif, TAN, is essential for telomere lengThmaintenance and a DNA damage response. Mol Cell Biol 2008; 28: 5736-5746
80. Chen S, Paul P, Price BD. ATM's leucine-rich domain and adjacent sequences are essential for ATM to regulate the DNA damage response. Oncogene 2003; 22: 6332-6339. (Pubitemid 37281681
81. Llorca O, Rivera-Calzada A, Grantham J, et al. Electron microscopy and 3D reconstructions reveal that human ATM kinase uses an armlike domain to clamp around double-stranded DNA. Oncogene 2003; 22: 3867-3874. (Pubitemid 36819660
82. Paull T T, Lee J H. The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 2005; 4: 737-740. (Pubitemid 41353819
83. Lee J H, Paull T T. A TM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308: 551-554. (Pubitemid 40570585
84. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506. (Pubitemid 36168436
85. Kozlov SV, Graham ME, Jakob B, et al. Autophosphorylation and ATM activation: Additional sites add to the complexity. JBiol Chem 2011; 286: 9107-9119
86. Sun Y, Xu Y, Roy K, et al. DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity. Mol Cell Biol 2007; 27: 8502-8509
87. Goodarzi AA, Jonnalagadda JC, Douglas P, et al. Autophosphorylation of ataxia-Telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 2004; 23: 4451-4461. (Pubitemid 39601970
88. Goodarzi A A, Noon A T, Deckbar D, et al. ATM signaling facilitates repair of DNA double-strand breaks associated wiThheterochromatin. Mol Cell 2008; 31: 167-177. (Pubitemid 352001394
89. Pilch D R, Sedelnikova O A, Redon C, et al. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003; 81: 123-129. (Pubitemid 37076234
90. Kinner A, Wu W, Staudt C, et al. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 2008; 36: 5678-5694
91. Barlow C, Liyanage M, Moens PB, et al. Atm selectively regulates distinct p53-Dependent cell-cycle checkpoint and apoptotic pathways. Nat Genet 1997; 17: 453-456. (Pubitemid 27518396
92. Matsuoka S, Rotman G, Ogawa A, et al. Ataxia telangiectasiamutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000; 97: 10389-10394
93. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281: 1674-1677
94. Falck J, Petrini JH, Williams BR, et al. The DNA damage-Dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002; 30: 290-294
95. Yazdi PT, Wang Y, Zhao S, et al. SMC1 is a downstream Effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 2002; 16: 571-582. (Pubitemid 34212490
96. Buscemi G, Savio C, Zannini L, et al. Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol 2001; 21: 5214-5222. (Pubitemid 32656416
97. Gary PH, Margossian HS, Taniguchi T, et al. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol 2006; 26: 7005-7015. (Pubitemid 44387648
98. Xu B, O'Donnell AH, Kim ST, et al. Phosphorylation of serine 1387 in Brca1 is specifi cally required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002 ; 62: 4588-4591
99. Hopfner K P, Karcher A, Craig L, et al. Structural biochemistry and interaction architecture of the DNA double-strand break repair Mre11 nuclease and Rad50-ATPase. Cell 2001; 105: 473-485. (Pubitemid 32520853
100. Williams RS, Moncalian G, Williams JS, et al. Mre11 dimers coordinate DNA end bridging and nuclease processing in doublestrand-break repair. Cell 2008; 135: 97-109
101. Riballo E, Kuhne M, Rief N, et al. Apathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 2004; 16: 715-724. (Pubitemid 39586530
102. Chen L, Morio T, Minegishi Y, et al. Ataxia-Telangiectasiamutated dependent phosphorylation of Artemis in response to DNA damage. Cancer Sci 2005; 96: 134-141. (Pubitemid 40425390
103. Beamish H, Kedar P, Kaneko H, et al. Functional link between BLM defective in Bloom's syndrome and the ataxia-Telangiectasiamutated protein, ATM. JBiol Chem 2002; 277: 30515-30523. (Pubitemid 34970744
104. Shafman T, Khanna K K, Kedar P, et al. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997; 387: 520-523. (Pubitemid 27235472
105. Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748-12752
106. Zhang J, Willers, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004; 24: 708-718. (Pubitemid 38057922
107. Stewart GS, Last JI, Stankovic T, et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, wiTh5762ins137 and 7271T → G mutations, showing a less severe phenotype. JBiol Chem 2001; 276: 30133-30141
108. Mailand N, Bekker-Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007; 131: 887-900. (Pubitemid 350138084
109. You Z, Shi LZ, Zhu Q, et al. CtIP links DNA double-strand break sensing to resection. Mol Cell 2009; 36: 954-969
110. Bree RT, Neary C, Samali A, et al. The switch from survival responses to apoptosis after chromosomal breaks. DNA Repair (Amst) 2004; 3: 989-995. (Pubitemid 38997941
111. Bai L, Zhu WG. p53: Structure, function and therapeutic applications. JCancer Mol 2006; 2: 141-153
112. Wang JY. Regulation of cell deaThby the Abl tyrosine kinase. Oncogene 2000; 19: 5643-5650
113. Yoshida K, Ozaki T, Furuya K, et al. ATM-Dependent nuclear accumulation of IKK-Alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 2008; 27: 1183-1188. (Pubitemid 351253185
114. Carcagno A L, Ogara M F, Sonzogni S V, et al. E 2F1 transcription is induced by genotoxic stress through ATM/ATR activation. IUBMB Life 2009; 61: 537-543
115. Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science 2010; 330: 517-521
116. Thanasoula M, Escandell JM, Suwaki N, et al. ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry wiThuncapped telomeres. EMBO J 2012; 31: 3398-3410
117. Bredemeyer AL, Sharma GG, Huang CY, et al. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 2006; 442: 466-470. (Pubitemid 44264797
118. Reina-San-Martin B, Chen HT, Nussenzweig A, et al. ATM is required for effi cient recombination between immunoglobulin switch regions. JExp Med 2004; 200: 1103-1110. (Pubitemid 39507050
119. Pan-Hammarström Q, Lä hdesmäki A, Zhao Y, et al. Disparate roles of ATR and ATM in immunoglobulin class switch recombination and somatic hypermutation. JExp Med 2006; 203: 99-110
120. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999; 59: 24-27. (Pubitemid 29062949
121. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26-29. (Pubitemid 29037699
122. Stankovic T, Stewart G S, Fegan C, et al. Ataxia telangiectasia mutated-Defi cient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002; 99: 300-309
123. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients wiThB-CLL. B lood 2 005; 1 06: 3 175-3 182
124. Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but infl uences rapid disease progression through loss of the remaining ATM allele. Haematologica 2012; 97: 142-146
125. Schaff ner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748-753
126. Swift M, Reitnauer P J, Morrell D, et al. Breast and other cancers in families wiThataxia-Telangiectasia. N Engl J Med 1987; 316: 1289-1294. (Pubitemid 17084026
127. Bevan S, Catovsky D, Marossy A, et al. Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia 1999; 13: 1497-1500. (Pubitemid 29465609
128. Yuille MR, Condie A, Hudson CD, et al. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 2002; 100: 603-609. (Pubitemid 34761125
129. Rudd M F, Sellick G S, Webb E L, et al. Variants in the ATMBRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 2006; 108: 638-644. (Pubitemid 44061365
130. Enjuanes A, Benavente Y, Bosch F, et al. Genetic variants in apoptosis and immunoregulation-related genes are associated wiThrisk of chronic lymphocytic leukemia. Cancer Res 2008; 68: 10178-10186
131. Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients wiThchronic lymphocytic leukemia containing an 11q deletion. JClin Oncol 2007; 25: 5448-5457
132. Cuneo A, Bigoni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological signifi cance. Haematologica 2002; 87: 44-51. (Pubitemid 34101112
133. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia:inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814-822
134. Stankovic T, Hubank M, Cronin D, et al. Microarray analysis reveals that TP53-And ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major diff erences in activating prosurvival responses. Blood 2004; 103: 291-300. (Pubitemid 38029951
135. Skowronska A, Parker A, Ahmed G, et al. Biallelic ATM inactivation signifi cantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. JClin Oncol 2012; 30: 4524-4532
136. Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profi le and predict disease progression. Haematologica 2012; 97: 47-55
137. Malek SN. The biology and clinical signifi cance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 2013; 32: 2805-2817
138. Schuh A, Becq J, Humphray S, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 2012; 120 : 4191-4196
139. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365 : 2497-2506
140. Carter A, Lin K, Sherrington P D, et al. Detection of p53 dysfunction by fl ow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425-428. (Pubitemid 39536594
141. Carter A, Lin K, Sherrington P D, et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006; 20: 737-740
142. Mohr J, Helfrich H, Fuge M, et al. DNA damage-induced transcriptional program in CLL: Biological and diagnostic implications for functional p53 testing. Blood 2011; 117: 1622-1632
143. Lin K, Adamson J, Johnson GG, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: Blockade at the level of p21 is associated wiThshort response duration. Clin Cancer Res 2012; 18: 4191-4200
144. Te Raa GD, Malcikova J, Pospisilova S, et al.; European Research Initiative on CLL (ERIC). Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 1849-1853
145. Best O G, Gardiner A C, Majid A, et al. Anovel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008; 22: 1456-1459. (Pubitemid 352006096
146. Navrkalova V, Sebejova L, Zemanova J, et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia:Application of functional test using doxorubicin. Haematologica 2013; 98: 1124-1131
147. Johnson G G, Sherrington P D, Carter A, et al. Anovel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res 2009; 69: 5210-5217
148. Ouillette P, Li J, Shaknovich R, Li Y, et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes Chromosomes Cancer 2012; 51: 1125-1132
149. Weston VJ, Oldreive CE, Skowronska A, et al. The PARP inhibitor olaparib induces signifi cant killing of ATM-Defi cient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116: 4578-4587
150. Martí n M, Terradas M, Tusell L, et al. ATM and DNA-PKcs make a complementary couple in DNA double strand break repair. Mutat Res 2012 Jan 2. [Epub ahead of print
151. Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATMor p53-Defi cient cancer cells through inhibition of ATR. Nat Chem Biol 2011; 7: 428-430
152. Kennedy R D, Chen C C, Stuckert P, et al. Fanconi anemia pathway-Defi cient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. JClin Invest 2007; 117: 1440-1449. (Pubitemid 46718432